Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study-Reference-Cited by-同舟云学术

Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study

Published:2016-06-29 Issue:9 Volume:18 Page:925-929
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Kaku K.¹,Enya K.²,Nakaya R.²,Ohira T.²,Matsuno R.²

Affiliation:

1. Department of Medicine; Kawasaki Medical School; Okayama Japan

2. Japan Development Center; Takeda Pharmaceutical Co. Ltd; Osaka Japan

Funder

Content Ed Net

Takeda Pharmaceutical Company

Astelas

AstraZeneca

Boehringer Ingelheim

Chugai

Daiichi-Sankyo

Dainippon Sumitomo Pharma

Kissei

Kowa

Mount Sylvia Diatomite

Novartis

Novo Nordisk

Sanofi

Sanwa Kagaku Kenkyusho

Taisho

Takeda Pharmaceuticals U.S.A.

Tanabe-Mitsubishi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12693/fullpdf

Reference12 articles.

1. GPR40: a therapeutic target for mediating insulin secretion (review);Feng;Int J Mol Med,2012

2. Treatment of type 2 diabetes by free fatty acid receptor agonists;Watterson;Front Endocrinol (Lausanne),2014

3. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist;Negoro;ACS Med Chem Lett,2010

4. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes;Araki;Diabetes Obes Metab,2012

5. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes;Leifke;Clin Pharmacol Ther,2012

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes;Biomedicine & Pharmacotherapy;2024-08

2. An adipocentric perspective of pancreatic lipotoxicity in diabetes pathogenesis;Journal of Endocrinology;2024-04-17

3. Role of microsomal metabolism in bromfenac-induced cytotoxicity;Chemico-Biological Interactions;2024-03

4. Role of sodium taurocholate cotransporting polypeptide (NTCP) in HBV-induced hepatitis: Opportunities for developing novel therapeutics;Biochemical Pharmacology;2024-01

5. G protein-coupled receptors and obesity;Frontiers in Endocrinology;2023-12-14